PARP16: A Potential Drug Target for Various Diseases (G54956)

Target Name: PARP16

NCBI ID: G54956

PARP16

PARP16: A Potential Drug Target for Various Diseases

PARP16 (C15orf30) is a gene that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. The PARP gene is located on chromosome 15 and encodes for the protein poly (ADP-ribose) polymerase (PARP). PARP is a enzyme that is involved in the repair of damaged DNA, and its dysfunction has been implicated in the development and progression of many diseases.

One of the key features of PARP is its ability to recognize and repair specific types of DNA damage. This is important because when DNA is damaged, it can no longer function properly, and this can lead to the development of genetic mutations that can cause diseases. PARP is able to recognize and repair DNA damage caused by a variety of factors, including radiation, chemicals, and errors in DNA replication.

In addition to its role in DNA repair, PARP is also involved in the regulation of cellular processes that are important for cell growth and division. It helps to ensure that the cell has enough copies of its genetic material to divide and that the division of the cell is properly regulated.

The dysfunction of PARP has been implicated in the development and progression of many diseases, including cancer. For example, studies have shown that PARP16 is often expressed in various types of cancer, and that its dysfunction is associated with poor prognosis in patients with these diseases. Additionally, the dysfunction of PARP has been implicated in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's.

Due to its involvement in so many cellular processes, and its potential as a drug target, PARP16 is an attractive target for researchers to investigate for new treatments for a variety of diseases. One approach that is being explored is the use of drugs that can inhibit the activity of PARP16 in order to treat diseases that are caused by its dysfunction. For example, studies have shown that inhibiting the activity of PARP16 has the potential to be a effective treatment for various types of cancer, including breast, ovarian, and colorectal cancers.

Another approach that is being explored is the use of drugs that can activate the activity of PARP16 in order to treat diseases that are caused by its dysfunction. For example, studies have shown that activating the activity of PARP16 has the potential to be an effective treatment for neurodegenerative diseases, such as Alzheimer's and Parkinson's.

In conclusion, PARP16 is a gene that has the potential to be a drug target (or biomarker) for the treatment of various diseases, including cancer. Its ability to recognize and repair specific types of DNA damage, as well as its involvement in the regulation of cellular processes, make it an attractive target for researchers to investigate for new treatments. Additionally, the dysfunction of PARP16 has been implicated in the development and progression of many diseases, including cancer, which further supports its potential as a drug target. Further research is needed to fully understand the potential of PARP16 as a drug target and to develop effective treatments for the various diseases associated with its dysfunction.

Protein Name: Poly(ADP-ribose) Polymerase Family Member 16

Functions: Intracellular mono-ADP-ribosyltransferase that plays a role in different processes, such as protein translation and unfolded protein response (UPR), through the mono-ADP-ribosylation of proteins involved in those processes (PubMed:22701565, PubMed:23103912, PubMed:25043379, PubMed:34314702). Acts as an inhibitor of protein translation by catalyzing mono-ADP-ribosylation of ribosomal subunits, such as RPL14 and RPS6, thereby inhibiting polysome assembly and mRNA loading (PubMed:34314702). Mono-ADP-ribosylation of ribosomal subunits is promoted by NMNAT2 (PubMed:34314702). Involved in the unfolded protein response (UPR) by ADP-ribosylating and activating EIF2AK3 and ERN1, two important UPR effectors (PubMed:23103912). May also mediate mono-ADP-ribosylation of karyopherin KPNB1 a nuclear import factor (PubMed:22701565). May not modify proteins on arginine or cysteine residues compared to other mono-ADP-ribosyltransferases (PubMed:22701565)

The "PARP16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PARP16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets